A commentary on 'The experience of neoadjuvant chemotherapy versus upfront surgery in resectable pancreatic cancer: a cross sectional study'
- PMID: 37402310
- PMCID: PMC10583943
- DOI: 10.1097/JS9.0000000000000588
A commentary on 'The experience of neoadjuvant chemotherapy versus upfront surgery in resectable pancreatic cancer: a cross sectional study'
Conflict of interest statement
No potential competing interests were disclosed by the authors.
Comment on
-
The experience of neoadjuvant chemotherapy versus upfront surgery in resectable pancreatic cancer: a cross sectional study.Int J Surg. 2023 Sep 1;109(9):2614-2623. doi: 10.1097/JS9.0000000000000495. Int J Surg. 2023. PMID: 37300888 Free PMC article.
References
-
- Tempero MA, Malafa MP, Al-Hawary M, et al. . Pancreatic adenocarcinoma, version 2.2021, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw 2021;19:439–457. - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
